Retatrutide 5mg 10mg cheap price

short description:

Name: Retatrutide

Specs: 5mg/vial*10vials/box 10mg/vial*10vial /box

Price: 5mg USD170/box 10mg USD340/box

Lab: Lianfu Bio

MOQ: 1 box

Send email to us

Product Detail

Our Service and Policy

Order Procedure

Product name: Retatrutide

Specification: 5mg*10vial /kit 10mg*10vials/kit

MOQ :1kit

Price: 5mg USD320/kit 10mg USD600/kit

Place of Origin: China

Retatrutide

Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus, obstructive sleep apnea, osteoarthritis, obesity and non-alcoholic fatty liver disease. The drug candidate is administered through subcutaneous and intravenous route. The drug candidate acts by targeting glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is a new molecular entity.

Retatrutide works in the treatment of obesity by targeting three different hunger regulating hormones: – GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the gut after eating. Retatrutide stimulates the beta-cells in the pancreas to secrete insulin.The drug is a peptide with amino acid sequence. It is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors. It has been shown to achieve a more than 24% mean weight reduction in non-diabetic obese or overweight adults.

Retatrutide is similar to Ozempic, Wegovy, and Mounjaro in that it is a once weekly injection of hormones that change the way we eat, leading to early feelings of fullness and decreased appetite.

But unlike Ozempic and Wegovy, which mimic only one hunger-regulating hormone (GLP-1), or Mounjaro, which mimics two hormones (GLP-1 and GIP), retatrutide is a single molecule that mimics three different hunger-regulating hormones: GLP-1, GIP, and glucagon. That “triple G” action, as some scientists termed it at the meeting, seems to have more potent effects on a person’s appetite and satisfaction with food.

In the trial published in the NEJM, patients with obesity who were given the highest weekly dose of retatrutide (12 mg) lost an average of 58 pounds in 11 months. Their weight was still going down even when the trial ended, suggesting that longer, bigger trials yet to be completed may deliver even more impressive weight loss results. Every patient on the highest dose of retatrutide lost at least 5% of their body weight, and a quarter of those participants lost 30% or more of their weight.

In a similar study of retatrutide for patients with Type 2 diabetes published in The Lancet, patients lost about 17% of their bodyweight in nine months, which is a remarkable feat, since it’s typically harder for patients with T2D to lose the same amount of weight as other people with overweight and obesity.